상세 보기
자료 필터
자료유형
발행연도
2010 ~ 2032
2010 2032
키워드
언어
전체 236건 중 71번부터 80번까지의 결과를 표시합니다.
2024
Article
Lazertinib in EGFR-Variant Non-Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors: A Nonrandomized Controlled Trial
- Hong, Min Hee ;
- Choi, Yoon Ji ;
- Ahn, Hee Kyung ;
- Lim, Sun Min ;
- Keam, Bhumsuk ;
- ... Kim, Ju Won ;
- 외 8명
- 2024-10
- JAMA Oncology
- American Medical Association
Article
Nationwide precision oncology pilot study: KOrean Precision Medicine Networking Group Study of MOlecular profiling-guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) KCSG AL-20-05
- 2024-10
- Esmo Open
- BMJ PUBLISHING GROUP
Article
A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17)
- 2024-09
- Esmo Open
- BMJ PUBLISHING GROUP
Conference
Circulating tumor DNA as a biomarker for neratinib and trastuzumab efficacy in HER2-mutated advanced solid tumors: Insights from KCSG AL20-17/KM23 phase II trial
- Lee, K. ;
- Lee, K-H. ;
- Kim, D-W. ;
- Yoon, J. S. ;
- Choi, W. ;
- ... Choi, Y. J. ;
- ... Lee, S. ;
- ... Kim, J. W. ;
- ... Kang, E. J. ;
- ... Park, I. H. ;
- 외 10명
- 2024-09
- 네덜란드
Conference
Integrative genomic analysis examines molecular and clinical disparities between bladder urothelial carcinoma and upper tract urothelial carcinoma
- Choi, Yoon Ji ;
- Kim, Jwa Hoon ;
- Lee, Jae-Lyun ;
- Bae, Woo Kyun ;
- Kim, Miso ;
- 외 9명
- 2024-06-01
- 미국
Conference
Phase II study to evaluate safety and efficacy of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors (KCSG AL20-17).
- Lee, Kyoungmin ;
- Lee, Kyung-Hun ;
- Kim, Dong-Wan ;
- Yoon, Jeesun ;
- Choi, Wonyoung ;
- ... Choi, Yoon Ji ;
- ... Lee, Soohyeon ;
- ... Kim, Ju Won ;
- ... Kang, Eun Joo ;
- ... Park, Inhae ;
- 외 10명
- 2024-06-01
- 미국